Harvia Q1 2026 slides: record revenue hits EUR 58.6M amid currency headwinds

Harvia posted record Q1 2026 revenue of EUR 58.6 million, up 12.7% year over year, with adjusted operating profit of EUR 12.9 million and operating free cash flow of EUR 12.0 million. Growth was broad-based across all regions, but reported results were held back by a weak U.S. dollar and the shares still fell 1.58% to EUR 41.1 as investors focused on valuation and temporary Q2 disruption from an IT system upgrade. The company also reaffirmed long-term targets, confirmed a EUR 0.77 per share dividend, and highlighted ongoing investments in digital sales and production capacity.

Analysis

The market is punishing quality because it is looking through the wrong horizon. The setup is not a deterioration in demand; it is a temporary timing mismatch where a system migration pushes revenue and gross margin into the next quarter while expenses hit now. That creates a classic “earnings air pocket” for a premium multiple stock: the business quality is intact, but the next print is likely to look mechanically softer, which is enough to keep valuation de-rating pressure in place.

The more important second-order effect is currency. With a very large North American mix, the translation drag can make underlying momentum look weaker than it really is, and that usually delays multiple expansion until FX stops being a headwind. If the dollar stabilizes, reported growth can re-accelerate sharply without any change in end demand, which means consensus may be underestimating how much operating leverage is hidden in the model once the IT transition is behind it.

Competitively, the company’s direct-to-consumer push and systems upgrade should improve channel control and data visibility, which matters more for margin durability than headline revenue. That said, the near-term risk is execution: any slippage in the go-live window, customer backorders, or incremental transition costs would likely extend the de-rating by another quarter. The key tell is not Q2 revenue alone, but whether Q3 shows the promised catch-up in both volume and margin conversion.

The contrarian view is that the stock may already be pricing the transition as if it were a demand issue. If the next two quarters confirm that lost timing is not lost sales, and if FX eases even modestly, the combination of low leverage, dividend support, and restored growth visibility can re-rate the equity faster than the market expects. This is a setup where the downside is mostly near-term optics, while the upside is driven by the market reclassifying the name from expensive cyclicality to durable compounding.

Key Decisions for Investors

• Go long on weakness over the next 1-2 weeks, but size it as a catalyst trade into Q2/Q3 rather than a core add; target a 10-15% rebound if the market starts pricing the deferred revenue catch-up instead of the timing noise.
• Use a call spread to express the thesis: buy 3-6 month upside exposure and finance it by selling further OTM calls, since the stock likely needs one clean quarter to re-rate but near-term upside may be capped by valuation skepticism.
• Pair trade: long the company vs. a euro-linked consumer/industrial name with similar multiple sensitivity but weaker cash conversion; the relative long should benefit if investors reward deferred margin recovery over headline EPS misses.
• Avoid chasing outright long before the Q2 print if you need clean risk control; the better entry is after any selloff tied to system-transition headlines, with a stop if Q3 commentary does not confirm margin recovery and delivery normalization.
• For existing holders, keep the position but monetize into strength ahead of the next earnings window; the risk/reward is favorable only if the market continues to overlook the balance-sheet strength and recurring dividend support.